OkudaDTLebrun- FrenayC. Radiologically isolated syndrome in the spectrum of multiple sclerosis. Mult Scler2024; 30: 630–636.
2.
OkudaDTKantarciOLebrun-FrénayC, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol2023; 93(3): 604–614.
3.
Lebrun- FrenayCSivaASormaniMP, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: The TERIS randomized clinical trial. JAMA Neurol2023; 80: 1080–1088.
4.
MontalbanXLebrun-FrenayCOhJ, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol2025.
5.
GoizetCLescaGDurrA, et al. Presymptomatic testing in Huntington’s disease and autosomal dominant cerebellar ataxias. Neurology2002; 59: 1330–1336.
6.
BernhardtBAZayacCPyeritzRE. Why is genetic screening for autosomal dominant disorders underused in families? the case of hereditary hemorrhagic telangiectasia. Genet Med2011; 13(9): 812–820.
7.
van der SteenstratenIMTibbenARoosRA, et al. Predictive testing for Huntington disease: Nonparticipants compared with participants in the Dutch program. Am J Hum Genet1994; 55(4): 618–625.
8.
GreenRCRobertsJSCupplesLA, et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med2009; 361: 245–254.
9.
GodinoLTurchettiDJacksonL, et al. Impact of presymptomatic genetic testing on young adults: A systematic review. Eur J Hum Genet2016; 24(4): 496–503.
10.
JastreboffAMAronneLJAhmadNN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med2022; 387: 205–216.
